Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 126-133

  Weigel, M T ^a   Banerjee, S ^b   Arnedos, M ^b   Salter, J ^b   A'Hern, R ^a   Dowsett, M ^a,b   Martin, L A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Abl; Aromatase inhibitor; Breast cancer; Endocrine resistance; PDGFR

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN AB1; PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS POTENTIAL; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

EID: 84871568254     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds240     Document Type: Article

References (40)

1. Nicholson RI, McClelland RA, Robertson JF et al. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999; 6: 373-387.
2. Ali S., Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2: 101-112.
3. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348: 2431-2442.
4. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
5. Johnston SR, Saccani-Jotti G, Smith IE et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995; 55: 3331-3338.
6. Gutierrez MC, Detre S, Johnston S et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogenactivated protein kinase. J Clin Oncol 2005; 23: 2469-2476.
7. Arpino G, Wiechmann L, Osborne CK et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008; 29: 217-233.
8. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631-643.
9. Ellis MJ, Tao Y, Young O et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006; 24: 3019-3025.
10. Weigel MT, Ghazoui Z, Lykkesfeldt AE et al. Experimental and clinical studies reveal the PDGF/Abl pathway as a novel therapeutic target in endocrine-resistant breast cancer [Abstract]. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. Abstract 209 2010. AACR, Philadelphia, PA.
11. Weigel MT, Ghazoui Z, Dunbier AK et al. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Res 2012; 14: R78.
12. Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res 2007; 97: 247-274.
13. Fleming TP, Saxena A, Clark WC et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992; 52: 4550-4553.
14. Corless CL, Schroeder A, Griffith D et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357-5364.
15. Sjoblom T, Shimizu A, O'Brien KP et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001; 61: 5778-5783.
16. Paulsson J, Sjoblom T, Micke P et al. Prognostic significance of stromal plateletderived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009; 175: 334-341.
17. van Agthoven T, Sieuwerts AM, Meijer D et al. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. Endocr Relat Cancer 2010; 17: 215-230.
18. Yuan ZM, Huang Y, Whang Y et al. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 1996; 382: 272-274.
19. Brasher BB, Van Etten RA. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem 2000; 275: 35631-35637.
20. Srinivasan D, Plattner R. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 2006; 66: 5648-5655.
21. Srinivasan D, Sims JT, Plattner R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 2008; 27: 1095-1105.
22. He X, Zheng Z, Song T et al. c-Abl regulates estrogen receptor alpha transcription activity through its stabilization by phosphorylation. Oncogene 2010; 29: 2238-2251.
23. Zhao H, Ou-Yang F, Chen IF et al. Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer. Neoplasia 2010; 12: 214-223.
24. Oh AS, Lahusen JT, Chien CD et al. Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells. Mol Cell Biol 2008; 28: 6580-6593.
25. Arnedos M, Drury S, Afentakis M et al. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer. J Clin Oncol 2010; 28: 15s (Suppl.; Abstract 1034).
26. Dowsett M, Ebbs SR, Dixon JM et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists. J Clin Oncol 2005; 23: 2477-2492.
27. Smith IE, Walsh G, Skene A et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007; 25: 3816-3822.
28. Andersen J, Orntoft TF, Poulsen HS. Immunohistochemical demonstration of estrogen receptors (ER) in formalin-fixed, paraffin-embedded human breast cancer tissue by use of a monoclonal antibody to ER. J Histochem Cytochem 1988; 36: 1553-1560.
29. Nupponen NN, Paulsson J, Jeibmann A et al. Platelet-derived growth factor receptor expression and amplification in choroid plexus carcinomas. Mod Pathol 2008; 21: 265-270.
30. Dowsett M, Smith IE, Ebbs SR et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005; 11: 951s-958s.
31. Carvalho I, Milanezi F, Martins A et al. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 2005; 7: R788-R795.
32. Coltrera MD, Wang J, Porter PL et al. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res 1995; 55: 2703-2708.
33. Pinhel IF, Macneill FA, Hills MJ et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 2010; 12: R76.
34. Jechlinger M, Sommer A, Moriggl R et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 2006; 116: 1561-1570.
35. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-1464.
36. Plattner R, Kadlec L, DeMali KA et al. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 1999; 13: 2400-2411.
37. Srinivasan D, Kaetzel DM, Plattner R. Reciprocal regulation of Abl and receptor tyrosine kinases. Cell Signal 2009; 21: 1143-1150.
38. Manley PW, Drueckes P, Fendrich G et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010; 1804: 445-453.
39. Chow LW, Yip AY, Loo WT et al. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. Cancer Lett 2008; 262: 232-238.
40. Arun B, Murray JL, Walters R et al. The combination of letrozole and imatinib mesylate for metastatic breast cancer. ASCO Breast Cancer Symposium; 2009; Abstract 214.